Отчет об анализе размера, доли и тенденций мирового рынка реагентов для биологической визуализации – обзор отрасли и прогноз до 2031 года

Анализ рынка биологических реагентов для визуализации

Рынок биологических реагентов для визуализации переживает значительный рост, обусловленный достижениями в технологиях визуализации и растущим спросом на раннюю диагностику заболеваний. Последние разработки в этом секторе включают внедрение высокочувствительных контрастных агентов и новых флуоресцентных красителей, которые повышают качество визуализации, сводя к минимуму побочные эффекты. Например, исследователи изучают радиофармацевтические препараты следующего поколения , нацеленные на определенные раковые клетки, повышая точность диагностики и мониторинг лечения в онкологии. Более того, рост методов молекулярной визуализации стимулировал потребность в более сложных реагентах, которые могут обеспечить понимание биологических процессов на клеточном уровне в режиме реального времени. Кроме того, растущая распространенность хронических заболеваний в сочетании со старением населения стимулирует увеличение инвестиций в реагенты для визуализации. Поскольку системы здравоохранения во всем мире отдают приоритет персонализированной медицине, ожидается, что спрос на биологические реагенты для визуализации будет продолжать расти, способствуя постоянным исследованиям и разработкам, направленным на улучшение диагностических и терапевтических результатов.

Размер рынка реагентов для биологической визуализации

Объем мирового рынка реагентов для биологической визуализации в 2023 году оценивался в 18,08 млрд долларов США, а к 2031 году, по прогнозам, он достигнет 32,67 млрд долларов США, при среднегодовом темпе роста 7,67% в прогнозируемый период с 2024 по 2031 год. Помимо аналитических данных о рыночных сценариях, таких как рыночная стоимость, темпы роста, сегментация, географический охват и основные игроки, рыночные отчеты, подготовленные Data Bridge Market Research, также включают в себя углубленный экспертный анализ, эпидемиологию пациентов, анализ разработки новых лекарственных препаратов, анализ цен и нормативную базу.

Тенденции рынка биологических реагентов для визуализации

« Растущая интеграция передовых технологий обработки изображений с искусственным интеллектом (ИИ)»

Global biologic imaging reagents market's one significant trend is the increasing integration of advanced imaging technologies with artificial intelligence (AI) to enhance diagnostic capabilities and efficiency. AI algorithms are being employed to analyze imaging data more accurately and rapidly, improving the detection of diseases at earlier stages. For instance, companies such as Thermo Fisher Scientific Inc. are developing AI-driven imaging solutions that assist researchers in interpreting complex biological images, thereby expediting the drug discovery process. In addition, the incorporation of AI in biologic imaging reagents facilitates the identification of subtle changes in biological structures, which is crucial for understanding disease progression and evaluating treatment efficacy. As a result, the demand for biologic imaging reagents that integrate AI technologies is expected to rise, driving market growth and innovation.

Report Scope and Biologic Imaging Reagents Market Segmentation 

Biologic Imaging Reagents Market Definition

Biologic imaging reagents are specialized substances used in medical and scientific imaging to enhance the visibility of biological tissues, structures, or processes. These reagents can include contrast agents, fluorescent dyes, radiopharmaceuticals, and other markers that facilitate the imaging of cells, tissues, or organs using various imaging modalities such as MRI, PET, CT, or fluorescence microscopy. Biologic imaging reagents help improve the clarity and accuracy of diagnostic imaging by binding to specific biomolecules or structures within the body, enabling healthcare professionals and researchers to detect diseases, monitor treatment responses, and study biological processes in detail.

Biologic Imaging Reagents Market Dynamics

Drivers

• Increasing Prevalence of Chronic Diseases

The increasing prevalence of chronic diseases is a significant driver for the biologic imaging reagents market, as conditions such as cancer, cardiovascular diseases, and neurological disorders necessitate advanced imaging techniques for early diagnosis and effective treatment planning. According to the World Health Organization (WHO), chronic diseases account for approximately 71% of all global deaths, with cancer alone expected to reach nearly 30 million cases by 2040, representing a 47% increase from 2020. Such alarming rise in cancer cases underscores the need for enhanced diagnostic capabilities, leading to greater demand for imaging reagents that can provide detailed insights into disease progression and treatment responses. In addition, cardiovascular diseases, which affect an estimated 422 million people globally, require precise imaging for risk assessment and management, further propelling the need for advanced biologic imaging solutions. Consequently, the surge in chronic disease incidence drives biologic imaging reagents market.

• Growing Demand for Personalized Medicine

The growing demand for personalized medicine is significantly driving the biologic imaging reagents market, as healthcare providers increasingly seek precise imaging techniques to develop tailored treatment plans for individual patients. Such shift necessitates highly specific imaging reagents that can accurately identify biomarkers associated with various diseases, such as cancer. For instance, targeted imaging agents like PET radiotracers are being developed to bind selectively to cancer cells, allowing for better visualization of tumor characteristics and response to therapies. As the focus on individualized treatment continues to grow, the demand for advanced biologic imaging reagents that facilitate these personalized strategies is expected to rise, driving the market growth.

Opportunities

• Growing Technological Advancements

Technological advancements in imaging modalities, such as improved resolution and sensitivity, are significantly expanding opportunities for the development of innovative biologic imaging reagents that enhance diagnostic capabilities. For instance, the advent of high-resolution MRI and PET scans has improved the ability to visualize small tumors and detect early-stage diseases, necessitating the creation of more sensitive imaging reagents. In addition, the development of multiplex imaging techniques, which enable the simultaneous visualization of multiple biomarkers, requires reagents that can effectively target and differentiate between various disease markers. Such advancements creates opportunities in the market and pave the way for more accurate diagnostics and personalized treatment strategies.

• Growing Research and Development in Biomedical Sector

The growth in research and development in the biomedical sector is significantly boosting the demand for biologic imaging reagents, particularly in critical fields such as cancer, neurology, and cardiology. Increased funding from government agencies and private investors is facilitating innovative research aimed at discovering new imaging techniques and agents. For instance, the National Institutes of Health (NIH) allocated over $42 billion for biomedical research in 2022, with a substantial portion directed toward cancer research. Collaborations between academic institutions and pharmaceutical companies, such as the partnership between Johns Hopkins University and AstraZeneca, have led to the development of groundbreaking imaging agents that enhance the detection of biomarkers associated with specific diseases. As funding continues to grow, the demand for advanced biologic imaging reagents will rise, fostering innovation and ultimately broadening opportunities in the market.

Restraints/Challenges

• High development costs

High development costs represent a significant challenge in the biologic imaging reagents market, as the creation of advanced reagents requires substantial investment in research and development. Such process often involves extensive laboratory testing, preclinical trials, and compliance with rigorous regulatory standards, all of which contribute to escalating expenses. For smaller companies and startups, these high costs can be particularly daunting, as they may lack the financial resources or access to funding needed to navigate the lengthy development process. Consequently, the financial burden may discourage innovation, limiting the introduction of novel imaging agents into the market and hampering overall market growth.

• Lengthy and Complex Regulations

Regulatory hurdles pose a significant challenge in the biologic imaging reagents market, as the approval process for these agents can be both lengthy and complex. In the U.S., for instance, imaging reagents must undergo rigorous evaluation by the Food and Drug Administration (FDA), which requires extensive clinical trials to demonstrate safety and efficacy. The FDA’s 510(k) pathway, while expedited, still necessitates substantial data submission, often leading to timelines of several months to years before a product can reach the market. Such intricate regulatory landscape delays the introduction of new imaging reagents and increases development costs, ultimately limiting innovation and access to advanced imaging solutions, thereby impeding overall market growth.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Biologic Imaging Reagents Market Scope

The market is segmented on the basis of class, modality, application, and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Class

• Contrast Reagents
• Optical Reagents
• Nuclear Reagents

Modality

• MRI
• Ultrasound
• X-ray and CT
• Nuclear
  • PET
  • SPECT
  • Other nuclear imaging modalities
• Optical Imaging
• Others

Application

• In Vitro
  • Proteomcs
  • Genomics
  • Cell Biology
• In Vivo

End User

• Diagnostic Laboratories
• Imaging Centers
• Life Science Companies
• Research and Academic Institutes
• Others

Biologic Imaging Reagents Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, class, modality, application, and end user as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America leads the biologic imaging reagents market due to its advanced healthcare infrastructure, characterized by cutting-edge technology and comprehensive medical facilities. The region also benefits from high per capita healthcare spending, enabling access to innovative imaging solutions that enhance diagnostic capabilities. In addition, increased patient awareness regarding the importance of early disease detection and the benefits of advanced imaging techniques further fuels market growth, as individuals seek out effective diagnostic options.

Asia-Pacific region is anticipated to experience substantial growth from 2022 to 2029, driven by significant unmet medical needs and robust economic development. Countries like India and China are making notable strides in enhancing their healthcare infrastructure, which plays a crucial role in addressing these needs. This ongoing investment in healthcare facilities and services is expected to further bolster the region's capacity to provide advanced medical solutions and improve overall patient care.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Biologic Imaging Reagents Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Лидерами рынка биологических реагентов для визуализации являются:

• Thermo Fisher Scientific Inc. (США)
• PerkinElmer (США)
• Гербе (Франция)
• Beckman Coulter, Inc. (США)
• БИОПРО Баден-Вюртемберг ГмбХ (Германия)
• Bracco SpA (Италия)
• Bayer AG (Германия)
• FUJIFILM VisualSonics, Inc. (Канада)
• GE Healthcare (США)
• Cardinal Health (США)
• Конинклийке Philips NV (Нидерланды)
• Сименс (Германия)
• Корпорация Advanced Proteome Therapeutics (США)
• Корпорация Promega (США)
• ABX advanced biochemical composites GmbH (Германия)

Последние разработки на рынке реагентов для биологической визуализации

• В сентябре 2023 года Bracco Imaging SpA заключила стратегическое партнерство с Subtle Medical, Inc. с целью разработки контрастных веществ на основе искусственного интеллекта для МРТ-визуализации. Это сотрудничество расширило рыночный охват компании и увеличило ее клиентскую базу.
• В сентябре 2023 года компания Revvity, Inc. официально запустила свой расширенный портфель визуализации, направленный на стимулирование инноваций в различных доклинических исследовательских приложениях. Это новое предложение включает в себя системы визуализации следующего поколения IVIS Spectrum 2 и IVIS SpectrumCT 2, которые устанавливают новые стандарты универсальности и чувствительности в оптической визуализации in vivo. Кроме того, компания представила решение для структурной визуализации Quantum GX3 microCT, отличающееся улучшенным разрешением и скоростью как для визуализации in vivo, так и для визуализации ex vivo. Эта система специально разработана для поддержки исследователей в изучении биологии заболеваний и эффективной оценке терапевтических кандидатов.

SKU-51958